Jasper acquires Kira in all-stock deal, plans $132M placement
What's the deal? Jasper Therapeutics (Nasdaq: JSPR) has completed an all-stock acquisition of Kira Pharmaceuticals, forming a combined biotech focused on biologic therapies for immunologically driven disorders. Alongside the deal, Jasper entered a private placement of non-voting convertible preferred stock expected to raise about $132 million, led by specialist life sciences investors.
What's the endgame? The combined pipeline centres on three programmes. KP-104 targets paroxysmal nocturnal hemoglobinuria and rare renal disorders; briquilimab addresses transplant and immunologic indications including SCID; and preclinical KP-701 targets autoantibody-mediated diseases.
What's the money? Kira also out-licensed KP-301 and KP-402 to Mirador Therapeutics for a $12 million upfront payment plus potential milestones. Jasper said pro-forma cash — including the placement and out-licensing proceeds — is expected to fund operations and multiple clinical milestones through the second half of 2028. The combined company continues to trade under the ticker JSPR.
Why now? The extended runway buys time for a run of catalysts. KP-104 has multiple Phase 2 readouts planned between Q4 2026 and Q2 2027, briquilimab is progressing toward an FDA pre-BLA meeting, and KP-701 targets a CTA/IND filing in Q1 2027 with first-in-human data in Q3 2027.
What could go wrong? The all-stock structure dilutes existing JSPR shareholders, and the convertible preferred placement may create further dilution down the line. Integration and clinical execution across the expanded pipeline remain the key risks.
The signal: The combination of an all-stock merger, a targeted placement, and an out-licensing deal shows small-cap biotechs stacking multiple financing levers to build scale and extend cash runways rather than relying on a single equity raise.
Read more: StockTitan
Image credit: Generated with Gemini
